Shares of Intrexon Corp. (NYSE:XON) traded up 3.6% on Wednesday . The company traded as high as $28.34 and last traded at $27.92, with a volume of 1,122,996 shares traded. The stock had previously closed at $26.96.

A number of analysts have recently weighed in on the company. Stifel Nicolaus reissued a “buy” rating and issued a $57.00 price objective on shares of Intrexon Corp. in a research report on Wednesday, April 13th. Griffin Securities reaffirmed a “buy” rating and set a $65.00 price target on shares of Intrexon Corp. in a research report on Tuesday, June 7th. Zacks Investment Research raised Intrexon Corp. from a “hold” rating to a “strong-buy” rating and set a $32.00 price target for the company in a research report on Tuesday, May 3rd. JMP Securities started coverage on Intrexon Corp. in a research report on Tuesday, May 3rd. They set an “outperform” rating and a $42.00 price target for the company. Finally, Vetr raised Intrexon Corp. from a “hold” rating to a “strong-buy” rating and set a $33.69 price target for the company in a research report on Wednesday, August 3rd. One investment analyst has rated the stock with a sell rating, three have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Intrexon Corp. presently has an average rating of “Buy” and a consensus price target of $48.37.

The firm’s 50-day moving average price is $25.46 and its 200-day moving average price is $29.73. The company’s market capitalization is $3.30 billion.

Intrexon Corp. (NYSE:XON) last posted its earnings results on Tuesday, August 9th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.26) by $0.16. The company earned $52.50 million during the quarter, compared to analysts’ expectations of $53.78 million. During the same quarter in the previous year, the business earned ($0.37) earnings per share. Intrexon Corp.’s revenue was up 17.0% compared to the same quarter last year. Equities research analysts expect that Intrexon Corp. will post ($1.32) earnings per share for the current fiscal year.

In other Intrexon Corp. news, CEO Randal J. Kirk bought 41,830 shares of the company’s stock in a transaction that occurred on Friday, May 13th. The shares were purchased at an average price of $23.92 per share, with a total value of $1,000,573.60. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

A number of institutional investors have bought and sold shares of XON. Dimensional Fund Advisors LP raised its position in Intrexon Corp. by 3.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 141,851 shares of the company’s stock valued at $4,278,000 after buying an additional 4,854 shares during the period. Trexquant Investment LP bought a new position in Intrexon Corp. during the fourth quarter valued at about $2,590,000. Wells Fargo & Company MN increased its position in Intrexon Corp. by 44.8% in the fourth quarter. Wells Fargo & Company MN now owns 274,040 shares of the company’s stock valued at $8,262,000 after buying an additional 84,759 shares in the last quarter. Bank of Montreal Can increased its position in Intrexon Corp. by 16.8% in the fourth quarter. Bank of Montreal Can now owns 40,010 shares of the company’s stock valued at $1,207,000 after buying an additional 5,742 shares in the last quarter. Finally, State of Wisconsin Investment Board increased its position in Intrexon Corp. by 2.5% in the fourth quarter. State of Wisconsin Investment Board now owns 35,410 shares of the company’s stock valued at $1,068,000 after buying an additional 880 shares in the last quarter.

Intrexon Corporation (Intrexon) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.